[1] Fukami M, Seki A,Ogata T, SHOX haploinsufficiency as a cause of syndromic and nonsyndromic short stature[J]. Mol Syndromol, 2016, 7(1):3-11.
[2] Lin L, Li M, Luo J,et al. A high proportion of novel ACAN mutations and their prevalence in a large cohort of Chinese short stature children[J]. JCEM, 2021, 106(7): e2711-e2719.
[3] 许珊珊,顾学范,潘慧,等.儿童青少年血清胰岛素生长因子-1及胰岛素因子结合蛋白-3的正常参考值研究[J].临床儿科杂志,2009,27(12):1105-1110.
Xu SS, Gu Xf, Pan H, et al.Study on normal reference values of serum insulin growth factor-1 and insulin factor binding protein-3 in children and adolescents[J]. Clin Pediatr Dent, 2009,27(12):1105-1110.(in Chinese)
[4] 中华医学会儿科学分会内分泌遗传代谢组,《中华儿科杂志》编辑委员会,梁雁.基因重组人生长激素儿科临床规范应用的建议[J].中华儿科杂志,2013,51(6):426-432.
[5] Gleghorn L, Ramesar R, Beijhton P, et al. A mutation in the variable repeat region of the aggrecan gene(AGCL) cause a form of spondyloepihyseal dysplasia associated with severe, premature osteoarthritis[J]. Am J Hum Genet, 2005,77(3):484-490.
[6] Yin LP, Zheng HX, Zhu H. Short stature associated with a novel mutation in the aggrecan gene: A case report and literature review[J].World J Clin Cases, 2022,10(9):2811-2817.
[7] 王莉莉,吴海瑛,谢蓉蓉,等.186例矮小症患者遗传学检测结果分析[J].临床儿科杂志, 2022,40(5):349-354.
Wang LL, Wu HY, Xie RR, et al. Analysis of genetic testing results in 186 patients with dwarfism[J]. J Clin Pediatr Dent, 2022,40(5):349-354.(in Chinese)
[8] 王晓艳,谢蓉蓉,吴海瑛,等.五个ACAN基因变异致身材矮小家系的临床及遗传学分析[J].中华医学遗传学杂志,2021,38(10):942-946.
Wang XY, Xie RR, Wu HY, et al. Clinical and genetic analysis of five short stature families caused by ACAN gene mutations[J].Chin J Med Genetics, 2021,38(10):942-946.(in Chinese)
[9] Stavber L, Hovnik T, Kotnik P, et al. High frequency of pathogenic ACAN variants including an intragenic deletion in selected individuals with short stature[J].Eur J Endocrinol, 2020,182(3):243-253.
[10] Sun J, Jiang L,Liu G, et al. Evaluation of growth hormone therapy in seven chinese children with familial short stature caused by novel[J]. Front Pediatr, 2022, 10:1-7.
[11] Dateki S. ACAN mutations as a cause of familial short stature[J]. Clinical Pediatric Endocrinology, 2017, 26(3): 119-125.
[12] Cao Y, Guan X, Li S, et al. Identification of variants in ACAN and PAPSS2 leading to spondyloepi (meta) physeal dysplasias in four Chinese families[J]. Mol Genet Genom Med, 2022, 10(5): e1916.
[13] 曾婷,廖林燕,李牛,等.ACAN基因变异致家族性身材矮小一家系报告[J].临床儿科杂志,2018,36(6):463-466.
Zeng T, Liao LY, Li N, et al. A family report on familial short stature caused by ACAN gene mutation[J]. J Clin Pediatr Dent, 2018,36(6):463-466.(in Chinese)
[14] Wang Y, Ge J, Ma J, et al. Short stature with precocious puberty caused by aggrecan gene mutation: A case report[J]. Medicine, 2020, 99(34): e21635.
[15] Gerver WJM, Gkourogianni A, Dauber A, et al. Arm span and its relation to height in a 2-to 17-year-old reference population and heterozygous carriers of ACAN variants[J]. Horm Res Paediat, 2020, 93(3): 164-172.
[16] Liang MH, Hui M, Hui PM, et al. Growth-promoting therapies may be useful in short stature patients with nonspecific skeletal abnormalities caused by acan heterozygous mutations: Six Chinese cases and literature review - endocr pract[J]. Endocr Pract, 2020, 26(11):1255-1268.
[17] Alexandrou E, Dauber A, Tyzinski L,et al. Clinical phenotype and musculoskeletal characteristics of patients with aggrecan deficiency[J]. Am J Med Genet A, 2022, 188(4): 1193-1203.
[18] Mancioppi V, Prodam F, Mellone S, et al. Retrospective diagnosis of a novel ACAN pathogenic variant in a family with short stature: A case report and review of the literature[J]. Front Genet, 2021, 12:1451.
[19] Wu S, Wang C, Cao Q, et al. The spectrum of ACAN gene mutations in a selected Chinese cohort of short stature: Genotype-phenotype correlation[J]. Front Genet, 2022,13:891040.
[20] Okamoto M,Hamada J,Ochi F,et al. Short stature in a child with a novel Aggrecan gene variant: A case report[J].Pediatr Int, 2022,64(1): e15116.
[21] Kim TY, Jang KM, Keum CW, et al. Identification of a heterozygous ACAN mutation in a 15-year-old boy with short stature who presented with advanced bone age: A case report and review of the literature[J]. Ann Pediatr Endocrinol Metab, 2020,25(4):272-276.
[22] Muthuvel G, Dauber A, Alexandrou E, et al. Treatment of short stature in aggrecan-deficient patients with recombinant human growth hormone: 1-year response[J]. JCEM, 2022, 107(5): e2103-e2109.
[23] 赵莉莉,朱一琳,袁珂,等.重组人生长激素改善ACAN基因变异致家族性矮小的疗效观察及文献复习[J].临床儿科杂志,2021,39(1):59-64.
Zhao LL, Zhu YL, Yuan K, et al. Clinical observation and literature review of recombinant human growth hormone in improving familial dwarfism caused by ACAN gene mutation[J].Clin Pediatr Dent, 2021,39(1):59-64.(in Chinese)
[24] Nilsson O, Aggrecanopathies highlight the need for genetic evaluation of ISS children[J]. Eur J Endocrinol, 2020, 183(2): C9-C10.